[go: up one dir, main page]

IN2013MU01127A - - Google Patents

Info

Publication number
IN2013MU01127A
IN2013MU01127A IN1127MU2013A IN2013MU01127A IN 2013MU01127 A IN2013MU01127 A IN 2013MU01127A IN 1127MU2013 A IN1127MU2013 A IN 1127MU2013A IN 2013MU01127 A IN2013MU01127 A IN 2013MU01127A
Authority
IN
India
Prior art keywords
tigecycline
solution
reconstitution
maltose
preparation
Prior art date
Application number
Inventor
Parikh Dhara
Patel Aditya
Bhaskar Dr Pallerla
Sehgal Ashish
Original Assignee
Astron Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54258937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2013MU01127(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astron Res Ltd filed Critical Astron Res Ltd
Priority to IN1127MU2013 priority Critical patent/IN2013MU01127A/en
Priority to SI201431458T priority patent/SI2978426T1/en
Priority to PL14782395T priority patent/PL2978426T3/en
Priority to EP14782395.9A priority patent/EP2978426B1/en
Priority to HUE14782395A priority patent/HUE047307T2/en
Priority to PT147823959T priority patent/PT2978426T/en
Priority to US14/779,889 priority patent/US9511145B2/en
Priority to ES14782395T priority patent/ES2766832T3/en
Priority to CA2905645A priority patent/CA2905645C/en
Publication of IN2013MU01127A publication Critical patent/IN2013MU01127A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a stable pharmaceutical composition of Tigecycline and process for the preparation of the same. The composition comprises Tigecycline and maltose wherein the pH of the bulk solution or solution after reconstitution is in between 3 - 6.
IN1127MU2013 2013-03-26 2013-03-26 IN2013MU01127A (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IN1127MU2013 IN2013MU01127A (en) 2013-03-26 2013-03-26
SI201431458T SI2978426T1 (en) 2013-03-26 2014-03-25 Stable tigecycline composition
PL14782395T PL2978426T3 (en) 2013-03-26 2014-03-25 Stable tigecycline composition
EP14782395.9A EP2978426B1 (en) 2013-03-26 2014-03-25 Stable tigecycline composition
HUE14782395A HUE047307T2 (en) 2013-03-26 2014-03-25 Stable tigecycline composition
PT147823959T PT2978426T (en) 2013-03-26 2014-03-25 Stable tigecycline composition
US14/779,889 US9511145B2 (en) 2013-03-26 2014-03-25 Stable tigecycline composition
ES14782395T ES2766832T3 (en) 2013-03-26 2014-03-25 Stable composition of tigecycline
CA2905645A CA2905645C (en) 2013-03-26 2014-03-25 Stable tigecycline composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1127MU2013 IN2013MU01127A (en) 2013-03-26 2013-03-26

Publications (1)

Publication Number Publication Date
IN2013MU01127A true IN2013MU01127A (en) 2015-05-01

Family

ID=54258937

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1127MU2013 IN2013MU01127A (en) 2013-03-26 2013-03-26

Country Status (9)

Country Link
US (1) US9511145B2 (en)
EP (1) EP2978426B1 (en)
CA (1) CA2905645C (en)
ES (1) ES2766832T3 (en)
HU (1) HUE047307T2 (en)
IN (1) IN2013MU01127A (en)
PL (1) PL2978426T3 (en)
PT (1) PT2978426T (en)
SI (1) SI2978426T1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021063468A1 (en) * 2019-10-02 2021-04-08 Anfarm Hellas S.A. Stable parenteral pharmaceutical composition containing tigecycline and process for the preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870059A (en) * 1985-11-27 1989-09-26 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Dehydration of hydrous matter with anhydrous maltose
EP0417193B1 (en) 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
USRE40183E1 (en) 1991-10-04 2008-03-25 Wyeth Holdings Corporation 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
DE19936281C2 (en) 1999-08-02 2002-04-04 Bayer Ag Freeze-drying process
CN1568999A (en) 2003-07-14 2005-01-26 南宁枫叶药业有限公司 Stable freeze dried formulation of spheroidine for medical use
CN102512429A (en) * 2005-03-14 2012-06-27 惠氏公司 Tigecycline compositions and methods of preparation
AR055336A1 (en) 2005-06-16 2007-08-22 Wyeth Corp PROCESS OF ELABORATION FOR THE PRODUCTION OF TIGECICLINE AS A RECONSTITUBLE POWDER, LIOFILIZED TIGECICLINE POWDER AND PRODUCT MADE THROUGH THE PROCESS
US9107929B2 (en) 2008-05-01 2015-08-18 Ranbaxy Laboratories Limited Stable parenteral formulations of tigecycline
WO2010017273A2 (en) 2008-08-06 2010-02-11 Wyeth Tigecycline formulations
RU2524665C2 (en) 2008-08-28 2014-07-27 Астразенека Аб Ceftaroline-including compositions and methods of treatment
JP6025712B2 (en) * 2010-05-12 2016-11-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド Tetracycline composition

Also Published As

Publication number Publication date
CA2905645C (en) 2021-02-16
CA2905645A1 (en) 2014-10-16
EP2978426A4 (en) 2016-11-30
PT2978426T (en) 2020-02-14
EP2978426A2 (en) 2016-02-03
US20160058865A1 (en) 2016-03-03
US9511145B2 (en) 2016-12-06
PL2978426T3 (en) 2020-05-18
SI2978426T1 (en) 2020-03-31
EP2978426B1 (en) 2019-11-13
HUE047307T2 (en) 2020-04-28
ES2766832T3 (en) 2020-06-15

Similar Documents

Publication Publication Date Title
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
MX2020005181A (en) Aminopyridine derivatives as tam family kinase inhibitors.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
IN2014MN00862A (en)
IL240731B (en) Antibody that binds to the p19 subunit of human il-23, process for producing same, pharmaceutical compositions comprising said antibody and its use in the treatment of cancer
MX2016004741A (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent.
PH12015500794A1 (en) Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same
MX2015009617A (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoq uinoline-3-carbonyl]-amino}-acetic acid.
MX2016000480A (en) High potency pancreatin pharmaceutical compositions.
IN2013MU03641A (en)
UY36250A (en) CRYSTAL FORM OF SOFOSBUVIR AND PROCESS FOR PREPARATION
MX2015003034A (en) Syringe containing a composition, especially a pharmaceutical composition, comprising immunoglobins, method for the production thereof and use of same.
MX2016009667A (en) Crystal form a of compound a monobenzoate and preparation method thereof and pharmaceutical composition comprising same.
GB2527233A (en) Composition comprising hydrocortisone
MX2015016603A (en) Corticosteroid compositions.
IN2013MU01127A (en)
IN2013CH05282A (en)
WO2014167575A3 (en) Stable tigecycline composition
IN2013CH04314A (en)
IN2013CH04330A (en)
IN2013CH05770A (en)
IN2013CH03945A (en)